Immatics Corp - IMTX Net earnings per share for the last four quarters

A unique target identification platform creates a powerful defensive moat for Immatics N.V. (IMTX). The growth rate history of net income per share YoY ttm demonstrates current volatility, where -80.70 determines the latest valuation metric. The company relies on its own manufacturing plants in the US and laboratories in Germany, while the development of T-cell therapy concepts is funded through external capital and grants.
IMTX (Immatics): analytical breakdowns and indicator data

The metric is calculated as the daily ratio of current annual net earnings per share to the value for the same period last year, allowing for the real-time tracking of value generation rates. By analyzing the year-over-year EPS dynamics over the last 12 months on the GURU.Markets platform, an investor can assess how the cancer immunotherapy partnerships of Immatics N.V. (IMTX) translate into the business's financial stability.